Vitiligo affects 1-2% of the world's population and has a great impact on the physical and mental health of patients. There is no targeted treatment to date. At present, theories about the pathogenesis of vitiligo include genetic factors, environmental factors, and autoimmunity, among which the autoimmune response plays a core role in melanocyte loss. In recent years, more and more studies have been conducted on the immune-related factors of vitiligo patients, such as the cytokines and chemokines derived from skin tissue cells, the activation of CD8+T cells, the abnormal immunosuppressive function of Treg cells and antigen-presenting function of DC cells, All these studies are of great significance for targeted therapy of vitiligo.
The goal of this research topic is to illustrate how melanocytes activate the autoimmune response, what changes occur in melanocytes, immune cells, and skin tissue cells during the occurrence of vitiligo, and whether they have important effects on the course of the disease. Although significant progress has been made in understanding autoimmunity in vitiligo, our knowledge remains incomplete. With the development of high-throughput sequencing technology, metabolomics, genomics, and other technologies can more conveniently describe the changes of these cells during vitiligo, which will provide important information for revealing the pathogenesis and seeking therapeutic targets for vitiligo.
This Research Topic aims to address the basic questions to reveal the pathogenesis of vitiligo. We encourage the submission in the form of Original Research, Reviews, and Perspective articles on addressing autoimmunity in vitiligo. We expect submissions based on (but not limited to):
• Clinical data analysis of patients with vitiligo
• The use and re-use of high-throughput data from individuals with vitiligo
• Innate and cellular immunology during vitiligo
• Metabolic changes of melanocytes and immune cells in the pathogenesis of vitiligo
• Updates on mechanisms of anti-melanocyte autoimmunity development in vitiligo
• Progress on autoantigen discovery and development of antigen-targeted therapeutics in vitiligo
Vitiligo affects 1-2% of the world's population and has a great impact on the physical and mental health of patients. There is no targeted treatment to date. At present, theories about the pathogenesis of vitiligo include genetic factors, environmental factors, and autoimmunity, among which the autoimmune response plays a core role in melanocyte loss. In recent years, more and more studies have been conducted on the immune-related factors of vitiligo patients, such as the cytokines and chemokines derived from skin tissue cells, the activation of CD8+T cells, the abnormal immunosuppressive function of Treg cells and antigen-presenting function of DC cells, All these studies are of great significance for targeted therapy of vitiligo.
The goal of this research topic is to illustrate how melanocytes activate the autoimmune response, what changes occur in melanocytes, immune cells, and skin tissue cells during the occurrence of vitiligo, and whether they have important effects on the course of the disease. Although significant progress has been made in understanding autoimmunity in vitiligo, our knowledge remains incomplete. With the development of high-throughput sequencing technology, metabolomics, genomics, and other technologies can more conveniently describe the changes of these cells during vitiligo, which will provide important information for revealing the pathogenesis and seeking therapeutic targets for vitiligo.
This Research Topic aims to address the basic questions to reveal the pathogenesis of vitiligo. We encourage the submission in the form of Original Research, Reviews, and Perspective articles on addressing autoimmunity in vitiligo. We expect submissions based on (but not limited to):
• Clinical data analysis of patients with vitiligo
• The use and re-use of high-throughput data from individuals with vitiligo
• Innate and cellular immunology during vitiligo
• Metabolic changes of melanocytes and immune cells in the pathogenesis of vitiligo
• Updates on mechanisms of anti-melanocyte autoimmunity development in vitiligo
• Progress on autoantigen discovery and development of antigen-targeted therapeutics in vitiligo